Table 3.
Outcomes reported in 80 randomised controlled trials (RCTs) evaluating surgical management of anterior-compartment prolapse
| Outcomes | Reporting studies |
|---|---|
| Prolapse treatment success rate | |
| Anatomical prolapse stage | 43 |
| Composite anatomical/functional success rate | 3 |
| Urethral mobility | 1 |
| Perioperative complications and observations | |
| Complications intra-/postoperatively | 23 |
| Postoperative hospital stay length | 11 |
| Blood loss intraoperatively | 6 |
| Duration of operation | 6 |
| Quality and time of recovery | 4 |
| Postoperative nausea and vomiting | 3 |
| Bleeding postoperatively (with/out vaginal pack use) | 2 |
| Constipation preoperatively | 2 |
| Blood pressure | 2 |
| Blood transfusion indicated | 2 |
| Heart rate change | 2 |
| Consistency of bowel movement postoperatively | 1 |
| Intra- and postoperative morbidity | 1 |
| Time to first postoperative bowel movement | 1 |
| Time to mobilisation | 1 |
| Pain | |
| Postoperative pain | 8 |
| Intraoperative requirement of analgesics | 1 |
| Total analgesic consumption | 1 |
| Pain level associated with first postoperative bowel movement | 1 |
| Postoperative catheterisation | |
| Postoperative UTI | 5 |
| Recatheterisation rates | 5 |
| Postoperative catheterisation duration | 4 |
| First postvoid residual volume | 4 |
| Time to normal spontaneous voiding | 2 |
| Acute urinary retention | 1 |
| Bacterial count in the urine | 1 |
| Catheter blockage | 1 |
| Day of spontaneous voiding | 1 |
| Diagnostic accuracy of different voiding trial methods | 1 |
| Mean residual urine volume pre- and postoperatively | 1 |
| Prediction of voiding dysfunction lasting >7 days. | 1 |
| Prolonged catheterisation | 1 |
| Pyelectasia | 1 |
| Residual urine volume | 1 |
| Urinary retention prevention with intravesically administered prostaglandin-E2 | 1 |
| Urinary retention rates | 1 |
| Postoperative vaginal packing | |
| Bleeding postoperatively (with/out vaginal pack use) (compared with menstrual average) | 1 |
| Bleeding postoperatively (with/out vaginal pack use) | 1 |
| Presence of vaginal haematoma | 1 |
| Presence of vaginal infection | 1 |
| Bother related to the pack | 1 |
| Presence of symptoms posttreatment | |
| Sexual dysfunction symptoms | 14 |
| Urinary symptoms | 11 |
| Prolapse symptoms postoperatively | 9 |
| Dyspareunia | 6 |
| SUI postoperatively | 5 |
| De novo SUI postoperatively | 4 |
| Change in urinary symptoms (any) | 3 |
| Prolapse symptoms severity | 3 |
| De novo urinary urgency | 2 |
| Postoperative urinary symptoms | 2 |
| Urinary symptoms severity | 2 |
| Bowel symptoms | 2 |
| Faecal incontinence | 2 |
| Postoperative bowel symptoms | 2 |
| Change in incontinence rates | 1 |
| De novo urinary symptoms | 1 |
| De novo voiding difficulty | 1 |
| Urgency and urge urinary incontinence | 1 |
| Worsening urinary symptoms (any) | 1 |
| Obstructed defecation | 1 |
| Back pain improvement | 1 |
| Change in a pelvic symptom score | 1 |
| Change of vaginal symptoms | 1 |
| Symptomatic prolapse improvement | 1 |
| Time of prolapse recurrence | 1 |
| De novo dyspareunia | 1 |
| Sexual function in partner | 1 |
| QoL and satisfaction with treatment | |
| QoL and impact from symptoms evaluation | 25 |
| Patient satisfaction with treatment | 11 |
| Surgeon satisfaction with operation | 2 |
| Patient acceptability of preoperative bowel preparation | 1 |
| Surgeon—ease of procedure | 1 |
| Treatment success evaluation | |
| Symptoms—presence posttreatment | 5 |
| Subjective cure rates | 3 |
| Cure of SUI postoperatively | 3 |
| Reoperation rates | 3 |
| Symptoms—bother change | 2 |
| Retreatment success rates | 1 |
| Symptom improvement | 1 |
| Functional recurrence | 1 |
| Healing abnormalities | 1 |
| Need for subsequent anti-incontinence surgery | 1 |
| Treatment of overactive bladder | 1 |
| Mesh-related outcomes | |
| Mesh erosion | 6 |
| Mesh shrinkage | 2 |
| Degree of morbidity in mesh vs. native tissue | 1 |
| Cost/effectiveness | |
| Cost-effectiveness of treatment | 2 |
| Cost of procedure | 1 |
| Recruitment feasibility | |
| Number of patients agreed to participate | 1 |
| Number of eligible patients | 1 |
| Physician acceptance and protocol | 1 |
| Rate of recruitment compliance | 1 |
UTI urinary tract infection, SUI stress urinary incontinence, QoL quality of life